에 대한 최신 뉴스 Grab Holdings (NASDAQ:GRAB) 주식

Grab Holdings

Grab Hldgs

Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore and Malaysia contributed 58% of revenue as of end-2021. Grab's main competitors in Southeast Asia are Foodpanda and Gojek, the ride-sharing arm of GoTo. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.

stpckchartbenzingaai2023_stock_market_trading_setup_close_up_of_multipl_8fe49d0f-1b96-4300-8432-bd41086c3559_1

CVNA

ENVX

GRAB

PLTR

TSLA

수요일(19일) 미국 주요 지수는 상승 마감했다 소매 투자자와 트레이더들의 주목을 받은 상위 종목은 다음과 같다. 팔란티어, 카바나, 에노빅스, 그랩 및 테슬라

수요일 주목받은 주식: 팔란티어, 카바나, 에노빅스, 그랩 및 테슬라

Grab

Equities

News

Markets

화요일(18일) 싱가포르의 저명한 기업가 아담 쿠는 그랩 홀딩스(NASDAQ:GRAB)의 투자 잠재력에 대한 의문을 제기했다. 동남아시아 슈퍼 앱인 그랩의 주가가 8동남아시아 슈퍼 앱의 주가가 화요일에 8.16% 상승한 5.30달러를 기록했고 지난 1년 동안 51.86% 상승했다.

지난 1년간 주가 52% 상승한 그랩, 취약한 &#34;경제적 해자&#34;와 성장 한계 경고

benzinga_deal_dispatch2

Entertainment

Asset Sales

Media

AMPS

BLCO

NSANY

PCHM

PSFE

Sony Group Corporation American Depositary Shares

SONY

TYO:4188

블록에 등장한 신규 기업들팜켐(OTC:PCHM), 약물 감지 땀 패치의 대표 기업이 전략적 대안을 모색하고 있다(즉, 인수합병 또는 매각). 이사회는 지금까지 은행가를 고용하는 것보다 독자적으로 상황을 처리할 수 있다고 자신감을 나타냈다. 관심 있는 인수자는 공식 데이터룸에 접근할 수 있다.

딜 디스패치: 팜켐이 독자 매각을 진행, TGI 프라이데이는 $1,900만 에 19개의 레스토랑 매각

Grab Holdings Limited - Class A Ordinary Shares

Grab Holdings Ltd

GrabAGun Digital Holdings Inc

South Korea is stepping boldly into a new era of crypto transparency—this time, powered by specialized, localized artificial intelligence. OpenLedger and Xangle have joined forces to develop Korea&#8217;s first crypto-native AI model, tailored explicitly for the unique regulatory, linguistic, and market-specific needs of the Korean crypto landscape.
The collaboration couldn&#8217;t be timelier. South Korea remains haunted by the dramatic collapse of TerraUSD in 2022, a $40 billion disaster that devastated retail investors and exposed severe vulnerabilities in the sector. In response, the Korean Financial Services Commission (FSC) has ramped up regulatory demands, requiring stricter disclosures, clearer reporting, and greater investor protection.
However, regulatory frameworks alone aren't enough. Amidst the complexity of crypto disclosures and market fluctuations, there&#8217;s a pressing need for tools that help investors navigate the evolving landscape with clarity and confidence and leveraging AI to bridge the gap between intricate regulatory language and accessible investor insights is the way to do it.
Most AI models were trained on Reddit threads and speculative noise. Combining decentralized AI with Korea&#8217;s most trusted data streams creates an authentic and transparent AI-driven experience tailored specifically to Korean users. Unlike most generic AI models, typically trained on English-language forums and speculative conversations, this new platform will offer precise, context-rich analysis grounded in the reality of the Korean crypto ecosystem. 
Since its inception in 2018, Xangle has built a reputation as Korea's go-to platform for crypto market intelligence and investor education, simultaneously supporting blockchain infrastructures and international project onboarding. Its deep understanding of local market dynamics coupled with OpenLedger's decentralized AI approach promises a genuinely transformative tool.
This is a refreshing departure from the industry norm, where AI tools often target English-speaking, institutional audiences. Korea, however, presents a radically different market. Nearly one in three Korean adults in their 20s and 30s holds crypto, underscoring the urgent need for accessible, effective, and localized investor guidance.
Beyond immediate investor benefits, this partnership reflects a critical shift in the global approach to AI. With dominant players like the U.S. emphasizing enterprise centralization and China focusing on state control, OpenLedger and Xangle present a compelling alternative: AI that is open, decentralized, and transparent from the ground up.
The timing also aligns perfectly with South Korea's legislative trajectory. With the National Assembly recently passing comprehensive crypto oversight laws and the upcoming implementation of the Digital Asset Basic Act (DABA), the market is primed for innovations that align regulatory rigor with practical usability.
Ultimately, this partnership illustrates a critical truth: For AI to genuinely revolutionize crypto markets, it must prioritize localization and transparency.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Opinion

Tech

Using Decentralized AI To Prevent The Next Crypto Collapse

<a href="https://www.wsj.com/tech/elon-musk-trump-openai-stargate-abu-dhabi-e2689615" title="https://www.wsj.com/tech/elon-musk-trump-openai-stargate-abu-dhabi-e2689615">https://www.wsj.com/tech/elon-musk-trump-openai-stargate-abu-dhabi-e2689615</a>

Global

MSFT

'Elon Musk Tried To Block Sam Altman's Big Ai Deal In The Middle East; Musk Warned That Trump Wouldn't Bless OpenAI Data-Center Project Unless His xAI Company Was Added' - WSJ

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is pulling the plug on its ACURATE neo2 and <a href="https://www.benzinga.com/general/health-care">Prime aortic valve systems</a>.
What Happened: The medical technology giant halted global sales and abandoned regulatory pursuits—including a long-sought FDA approval—after escalating demands from health authorities rendered the effort too costly. 
Despite the setback, the Marlborough, Massachusetts-based company signaled confidence in its broader portfolio, affirming that it remains on track to hit its financial targets for the quarter and full year.
Also, Boston Scientific is no longer pursuing U.S. Food And Drug Administration (FDA) approval for ACURATE.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
The company based its decision on recent discussions with regulators. There have been increased clinical and regulatory requirements to maintain regulatory approvals in global markets.
The additional resources and investments needed to satisfy these requirements are prohibitive for the company.
Boston Scientific, in an SEC <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000885725/000088572525000033/bsx-20250528.htm">filing</a>, stated that it expects to achieve organic sales guidance for the second quarter and 2025.
<ul class="wp-block-list">
<li>Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and <a href="https://www.benzinga.com/general/health-care/25/04/44952308/boston-scientific-raises-annual-outlook-after-strong-heart-devices-sales-in-q1-announces-cfo-transition" target="_blank" rel="noreferrer noopener">10%-12%, respectively</a>.</li>
<li>The company estimates 2025 adjusted EPS of $2.87-$2.94 compared to prior guidance of $2.80-$2.87 and the consensus of $2.86.</li>
<li>The company estimates second quarter 2025 net sales growth of approximately 17.5%-19.5% on a reported basis and approximately 13%-15% on an organic basis, with adjusted EPS of 71-73 cents compared to consensus of 71 cents.</li>
</ul>
The company is not reaffirming its second quarter and full year 2025 GAAP EPS guidance and expects to provide more information during its second quarter 2025 earnings call.
<ul class="wp-block-list">
<li>Boston Scientific estimated 2025 GAAP earnings of $1.86-$1.93 per share and second-quarter earnings of $0.45&nbsp;to&nbsp;$0.47 per share.</li>
</ul>
Price Action: Boston Scientific stock is down 0.98% at $105.13 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45643848/macys-feels-tariffs-and-consumer-spending-heat-cuts-profit-forecast" target="_blank" rel="noreferrer noopener">Macy&#8217;s Feels Tariffs And Consumer Spending Heat, Cuts Profit Forecast</a></li>
</ul>
Image: Shutterstock

Earnings

Large Cap

Health Care

Movers

Trading Ideas

General

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

<a href="https://www.ft.com/content/2c0db765-03ac-4820-8a02-806469848bee">https://www.ft.com/content/2c0db765-03ac-4820-8a02-806469848bee</a>

CDNS

SNPS

'Trump Orders US Chip Designers To Stop Selling To China; US Commerce Dept Told Electronic Design Automation Groups, Including Cadence, Synopsys, Siemens EDA, To Stop Supplying Their Technology To China' - Financial Times

WIIM

Shares of Synopsis and Cadence Design Systems are trading lower following a report indicating President Trump ordered chip designers to stop selling to China.

Cryptocurrency markets were down on Wednesday despite Vice President JD Vance&#8217;s vow of support for the digital asset industry at the Bitcoin <a href="https://www.benzinga.com/topic/bitcoin">Conference in Las Vegas.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$107,671</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,647</td>
<td>-1.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$170.62</td>
<td>-4.6%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.25</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2192</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.0000141</td>
<td>-2.9%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume increasing by 12% and daily active addresses down by 8%.</li>
<li>Coinglass data reports 81,179 traders were liquidated in the past 24 hours for $203 million.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45653063/coin-of-the-day-sui-wobbles-after-exploit-can-it-rebound">Coin Of The Day: SUI Wobbles After Exploit—Can It Rebound?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45654053/blackrock-to-take-10-stake-in-circles-ipo">BlackRock To Take 10% Stake In Circle&#8217;s IPO</a></li>
<li><a href="https://www.benzinga.com/25/05/45645265/dogecoin-slips-to-0-22-as-liquidations-spike-200-crucial-support-at-0-21">Dogecoin Slips To $0.22 As Liquidations Spike 200%, Crucial Support at $0.21</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45652549/vice-president-jd-vance-predicts-100m-bitcoin-holders-the-us-ought-to-be-leaning-into-bitcoin">Vice President JD Vance Predicts 100M Bitcoin Holders: &#8216;The US Ought To Be Leaning Into Bitcoin</a></li>
</ul>
Trader Notes: Prominent analyst Ali Martinez <a href="https://x.com/ali_charts/status/1927756641987871184">pointed out</a> that $106,800 is a crucial support zone for Bitcoin that needs to hold to prevent a steeper drop.
Trader Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1927781129261666714">said</a> he is not rushing into positions and doesn&#8217;t know where the market will go in the short term, advocating for a &#8220;move slow&#8221; approach in tough conditions.
Trader Altcoin Psycho <a href="https://x.com/AltcoinPsycho/status/1927754530906632306">sees</a> a &#8220;big moment&#8221; coming up for Solana, with $140 to $150 as a &#8220;great zone&#8221; for bids in case price declines to that level.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">big moment coming up for solana as it approaches the mid-point of this 6 month range. this type of price compression under resistance has resolved well for bulls lately. but in case it doesn&#39;t, $140-$150 is a great zone for spot bids imo <a href="https://t.co/mI7xK2EYOl">pic.twitter.com/mI7xK2EYOl</a>
&mdash; Psycho (@AltcoinPsycho) <a href="https://twitter.com/AltcoinPsycho/status/1927754530906632306?ref_src=twsrc%5Etfw">May 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45646680/trump-familys-expanding-crypto-ties-raise-questions-on-ethics-influence-and-investor-risk">Trump Family&#8217;s Expanding Crypto Ties Raise Questions On Ethics, Influence, And Investor Risk</a></li>
</ul>
Image: Shutterstock

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Slide As VP Vance Pledges Crypto Support

Rocket Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and intellectual disability</a>.
A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an <a target="_blank" href="https://www.benzinga.com/25/05/45621333/rocket-pharma-reports-patient-death-in-rare-disease-gene-therapy-trial-fda-puts-clinical-hold" rel="noreferrer noopener">acute systemic infection</a>.
Needham analyst Gil Blum downgraded Rocket Pharmaceuticals from Buy to Hold, with a Nil price forecast from $42 earlier. The analyst cited increased uncertainty around the company&#8217;s main value driver as the key reason for the downgrade.
Also Read: <a href="https://www.benzinga.com/government/regulations/25/05/45340465/bill-ackman-slams-subsidies-for-contributing-to-37-trillion-national-debt-hails-trumps-drug-price-order">Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump&#8217;s Drug Price Order</a>
&#8220;We continue to have a favorable view of RP-A501&#8217;s efficacy; however, we see increased uncertainty for the product given safety concerns,&#8221; Blum said in an analyst note.
Blum anticipates limited readthrough to Rocket&#8217;s other AAV programs, which utilize simpler immunosuppression regimens.
Chardan Research analyst Geulah Livshits also lowered its price target from $46 to $17 while <a href="https://www.benzinga.com/quote/RCKT/analyst-ratings" target="_blank" rel="noreferrer noopener">maintaining the Buy rating</a>.
While the disclosure does not negate the benefit reported for the program, the patient death and commentary regarding instances of TMA impact the benefit/risk profile of RP-A501, Livshits said in an analyst note.
Livshits reduced the probability of success from 70% to 40%, given CBER leadership&#8217;s focus on benefit/risk, pending more details regarding agency feedback and next steps.
The analyst projects a slower uptake among the Danon population (3.6% by 2030E), assuming greater caution among prescribers.
Chardan notes the company hasn&#8217;t revealed how many patients have been treated in the trial so far but said the study is currently over-enrolled, with more patients ready to begin treatment.
Management mentioned several possible next steps, such as switching to a simpler immunomodulatory treatment, using existing complement inhibitors known to be safe, and continuing to exclude patients who are genetically predisposed to complement activation.
Chardan highlights that it&#8217;s still unclear whether other immunomodulatory treatments could reduce the risk of TMA. There&#8217;s no timeline for when the company might align with the FDA and restart the trial. Additional changes like enrolling more patients may be required, which could cause further delays.
Given this uncertainty, the topline results are expected to come later than the previously guided mid-2026 timeframe.
Other analyst reactions:
<ul class="wp-block-list">
<li>Jefferies downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to $2.5.</li>
<li>Leerink Partners downgraded Rocket Pharmaceuticals from Outperform to Market Perform, lowering the price target from $37 to $8.</li>
<li>Scotiabank maintains Rocket Pharmaceuticals with a Sector Outperform, lowering the price target from $51 to $19.</li>
</ul>
Price Action: RCKT stock is trading higher by 6.44% to $2.48 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45655477/analyst-bullish-on-ultragenyx-poised-for-growth-with-six-drug-approvals-expected-by-2028">Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028</a></li>
</ul>
Image via Shutterstock

Analyst Color

Biotech

Downgrades

Price Target

Analyst Ratings

RCKT

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is in the news with its <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45617449/salesforce-strikes-8-billion-acquisition-to-boost-ai-and-data-cloud-power">$8 billion buyout </a>of data management company Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>), an ambitious foray into the AI and data integration business. But the tech behemoth isn&#8217;t only in the spotlight for the deal –investors are also eagerly <a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45646698/salesforce-inc-ai-ambitions-vs-stock-realities-ahead-of-q1-earnings-reveal">awaiting its fiscal Q1 2026 earnings release</a>, due after the market close Wednesday. Between a fresh M&amp;A appetite and expanding AI roots, CRM-focused funds could be on the cusp of a data-driven rally.
ETFs In The Spotlight
The Informatica acquisition and the expected earnings release have implications for a number of <a href="https://www.benzinga.com/etfs">ETFs that have big stakes in Salesforce</a>:
iShares Expanded Tech-Software Sector ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>): 7.4% weightage
First Trust Dow Jones Internet Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDN#NYSE">FDN</a>): 5.4% weightage
FT Vest Dow Jones Internet &amp; Target Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FDND#BATS">FDND</a>): 5.4% weightage
These ETFs would stand to benefit if Salesforce&#8217;s quarterly earnings beat or meet forecasts and if the market perceives the Informatica acquisition as a strategic play in the growing AI space.
Can Salesforce Deliver?
Analysts are calling for Salesforce to post adjusted earnings per share (EPS) of $2.55 on revenue of $9.75 billion, improving year over year from $2.44 EPS and $9.13 billion in revenue. Such a performance would demonstrate the company&#8217;s ongoing growth trend, but at a more tempered rate than what it experienced during its previous years of explosive expansion.
The earnings announcement is especially important since it will give us clues on how Salesforce&#8217;s recent strategic actions, such as acquiring Informatica, will affect its financial well-being and competitive standing in the AI-powered enterprise software industry.
Bottom Line
The dual emphasis by Salesforce on strategic acquisitions as well as strong earnings performance make it an important contributor to the AI and enterprise software industries. Both investors and ETF observers will be listening to the Q1 earnings announcement for signals about the direction of the company and the wider ramifications for tech-themed investment vehicles.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45649748/abercrombie-is-hot-again-heres-why-your-retail-etf-didnt-get-the-memo">Abercrombie Is Hot Again — Here&#8217;s Why Your Retail ETF Didn&#8217;t Get The Memo</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

ETFs

First Trust Dow Jones Internet Index Fund

First Trust Exchange-Traded Fund IV FT Vest Dow Jones Internet & Target Income ETF

FDND

INFA

CRM-Powered ETFs In Focus As Salesforce Bets Big On AI With $8B Informatica Deal Ahead Of Q1 Results

BofA Securities analyst Peter T. Galbo initiated coverage on Primo Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>),<a target="_blank" href="https://www.benzinga.com/quote/PRMB/analyst-ratings" rel="noreferrer noopener"> with a price forecast of $42.</a>
Galbo notes that Primo Brands stock is expected to appreciate over the next 12 months as the company realizes cost synergies, targeting $300 million in EBITDA by 2026.
If valuation multiples stay steady, this should support growth in enterprise and equity value.
Also Read:<a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45582935/ftc-scraps-pepsico-price-discrimination-case-in-3-0-vote-marking-major-shift-as-trump-era-leadership-reverses-biden-crackdown" rel="noreferrer noopener"> FTC Scraps PepsiCo Price Discrimination Case In 3-0 Vote, Marking Major Shift As Trump-Era Leadership Reverses Biden Crackdown</a>
Additional positives include bottled water&#8217;s rising share in U.S. liquid refreshment beverages and reduced focus on the category by other CSD producers, which could improve overall profitability.
The North American-based bottled and packaged water producer, which has 30 brands, including Poland Spring and Pure Life, was formed from the November 2024 merger of Primo Water and Blue Triton.
Galbo recalls that Primo Brands initially projected ~$200 million in cost synergies by 2026 at the time of its merger, later raising the target to ~$300 million (22% of FY24 combined adjusted EBITDA) during its February 2025 investor day.
While such projections are often met with skepticism, in Primo&#8217;s case, the company has clear overlapping costs to cut across brands, headcount, factories, fleets, and depots over the next seven quarters.
Favorably, by the end of 1Q25, Primo was already achieving ~$20 million in quarterly synergies, with limited reliance on harder-to-achieve revenue synergies.
The analyst observes that U.S. bottled water has outpaced total liquid refreshment beverages. This has boosted bottled water&#8217;s volume share to 38.4%, up from 36.7% in 2019 and 30.7% in 2014.
The trend is expected to persist as U.S. consumers increasingly favor healthier options over carbonated soft drinks.
Galbo sees additional support for Primo Brands&#8217; 3%-5% annual net sales growth target in its ongoing expansion of premium offerings, including Saratoga and Mountain Valley.
For FY25, the analyst&#8217;s adjusted EBITDA forecast of $1.610 billion includes $200 million of synergies, implying the remaining $63 million of incremental YoY EBITDA is driven almost entirely by sales growth as opposed to underlying operational improvement.
Likewise, the FY26 EBITDA assumes no underlying operational improvement, with the analyst&#8217;s $1.756 billion estimate driven mainly by $100 million of synergies.
Price Action: PRMB shares are trading higher by 2.95% to $33.17 at last check Wednesday.
Read Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45581845/judge-blocks-trumps-mass-federal-layoffs-citing-need-for-congressional-approval" target="_blank" rel="noreferrer noopener">Judge Blocks Trump's Mass Federal Layoffs, Citing Need For Congressional Approval</a></li>
</ul>
Photo: Shutterstock

PRMB

Primo Brands Coverage Initiated: Analyst Sees EBITDA Gains From Cost Cuts, Bottled Water Momentum

One middle-class budgeter had a cold brew of a wake-up call when they opened their finance app and realized their <a href="https://www.benzinga.com/news/earnings/25/04/45084597/starbucks-misses-q2-earnings-estimates-ceo-says-optimism-has-turned-into-confidence-i-see-more-opportunity-than-i-imagined">Starbucks habit </a>had quietly snowballed into a four-digit expense.
"Just realized I spent $1,089 at Starbucks over the past 7 months. What the actual hell am I doing??" <a href="https://www.reddit.com/r/MiddleClassFinance/s/jRzrmhV0Cx">the Reddit user wrote</a>, bewildered. "Somehow I went from $45 in January to $334 in April?? And then still dropped $237 in May even after trying to ‘cut back.' I basically have a coffee mortgage at this point."
Yes, a coffee mortgage. And they're not alone.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
From drive-thru cold foams to double matcha oatmilk lattes, Americans love their Starbucks — maybe a little too much. In fact, nearly 50% of U.S. consumers picked Starbucks as their go-to brand, according to a <a href="https://www.statista.com/statistics/1327923/favorite-coffee-brands-among-us-consumers/">2023 Statista survey</a>. That's not just a caffeine preference — that's loyalty with whipped cream on top.
The Redditor even attached a chart for "curious caffeine addicts," showing just how fast those $4 pick-me-ups morphed into twice-a-day $7 matchas. And the comments? A mix of confessions, judgment, and unsolicited frugal advice.
"No lie, it feels good when they don't even have to ask your name for the order anymore," one user said. "Signed, someone who isn't brave enough to see what they used to spend a year at Starbucks."
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a>
Another was more blunt: "Have you considered learning to make the coffee you like at home? Even if your Starbucks drink of choice is one of their fancy lattes, you've spent more in the last 7 months than it costs to buy a really nice espresso machine."
That's a fair point — especially considering what some finance pros have to say. <a href="https://www.benzinga.com/personal-finance/24/07/39693693/suze-orman-tells-oprah-instead-of-starbucks-everyday-a-25-year-old-putting-100-a-month-into-roth">Suze Orman famously warned</a> that your daily coffee habit could be tanking your financial future, once saying, "You are peeing $1 million down the drain" by buying coffee out instead of investing the money. Kevin O'Leary — Mr. Wonderful himself — <a href="https://www.benzinga.com/personal-finance/25/02/43946260/kevin-oleary-says-people-waste-15k-a-year-on-stupid-stuff-like-buying-lunch-at-work-it-costs-you-99-cents-to-make-a-sandwich">called it "stupid" spending</a> and swore he's never bought a cup of coffee in his life unless it came from his own kitchen.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
To put it in perspective: $1,089 is roughly what some Americans pay in rent or utilities. That's a weekend getaway. A starter investment portfolio. Or yes, a top-tier espresso machine with enough money left over for fancy syrups and a milk frother.
So while no one's saying to ditch your favorite green straw forever, it might be worth asking: Are you sipping joy — or just swiping into autopilot?
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Just Realized I Spent $1,089 at Starbucks in 7 Months' — A Middle-Class Coffee Addict Wonders If Blowing a Mortgage Payment on Lattes Is Normal

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock has soared nearly 500% over the past year driven by its positioning in the AI space. One analyst believes the stock has a lot more runway ahead with the AI revolution still <a href="https://www.benzinga.com/government/regulations/25/05/45403100/bullish-for-nvidia-tesla-palantir-microsoft-alphabet-amazon-ai-revolution-is-coming-to-the-saudi-kingdom-says-wedbushs-dan-ives">in its early stages</a>.
What To Know: Wedbush&#8217;s Dan Ives famously calls Palantir the &#8220;Messi of AI&#8221; because he expects the company to be one of the biggest beneficiaries of the AI boom. He&#8217;s been right so far, and he&#8217;s not pulling back on his bullish stance in the slightest.
Wednesday on CNBC&#8217;s &#8220;Squawk On The Street,&#8221; Ives predicted that Palantir stock will more than triple in the coming years and trade above $400 per share.
&#8220;That&#8217;s why it&#8217;s the &#8216;Messi of AI.&#8217; I believe we&#8217;re talking about a trillion-dollar market cap for Palantir in the next few years, and I think when you look at what [Alex] Karp and Palantir are doing, they, along with Nvidia, will be leading the AI revolution,&#8221; Ives said.
The other massive beneficiary of AI has been NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which is scheduled to report earnings after the market close on Wednesday. Ives expects the results to act as a &#8220;bright green light&#8221; for tech investors as demand continues to easily outweigh supply. 
There&#8217;s only one chip in the world fueling the AI revolution and that&#8217;s Nvidia&#8217;s, Ives said, adding that AI is driving the fourth Industrial Revolution. He expects Nvidia&#8217;s quarterly report to be the catalyst that kicks off a run to new highs for tech.
Check This Out: <a href="https://www.benzinga.com/25/05/45644145/nvidia-stock-is-bullish-ahead-of-q1-earnings-but-will-h20-chip-woes-dampen-the-party">Nvidia Bullish Ahead Of Q1 Earnings, But Will H20 Chip Woes Dampen The Party?</a>
Many analysts disagree with Ives on Nvidia and Palantir, especially Palantir, given its massive surge over the past year and its becoming one of the best-performing names in the S&amp;P 500.
Ives told CNBC that many analysts hated Palantir when it hit $25, despised it when it hit $50 and $100, but the deals keep coming in and the company is doing it without a traditional sales team. 
&#8220;I believe it&#8217;s a trillion dollar market cap in the next two to three years, and I think look, haters hate on this one, but I think they continue to underestimate the pure success that they&#8217;re seeing,&#8221; Ives said. 
&#8220;Karp, he&#8217;s playing chess, others are playing checkers. And I think you are starting to realize more and more in government, enterprise, and that&#8217;s why you cannot talk AI revolution without saying Palantir.&#8221;
In order for Palantir to reach a $1 trillion market cap valuation, the stock would need to climb to $427.35 per share. Palantir had a market cap of $291.19 billion as of Tuesday&#8217;s close. 
PLTR Price Action: <a href="http://benzinga.com/quote/PLTR">Palantir shares</a> were up 1.15% at $124.81 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45636050/palantir-partners-with-bain-company-to-accelerate-global-enterprise-ai-adoption">Palantir Partners With Bain &amp; Company To Accelerate Global Enterprise AI Adoption</a></li>
</ul>
Photo: slyellow/Shutterstock.

Long Ideas

NVDA

Tech Analyst Expects Palantir Stock To Rise Above $400 As AI Revolution  Kicks Into Gear

On Wednesday, William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rare genetic diseases</a>.
Since 2017, the company has commercialized four products, which generated $560 million in revenue in 2024, up 29% year-over-year. In the first quarter of 2025, sales increased <a href="https://www.benzinga.com/pressreleases/25/05/g45234765/ultragenyx-reports-first-quarter-2025-financial-results-and-corporate-update" target="_blank" rel="noreferrer noopener">28% to $139.29 million</a>.
Ultragenyx expects fiscal 2025 sales of $640 million-$670 million versus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $655.02 million</a>.
&#8220;We anticipate Ultragenyx&#8217;s legacy products will continue to provide a strong revenue foundation for the company through the early 2030s,&#8221; writes William Blair analyst Sami Corwin.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44523017/ultragenyx-is-uniquely-positioned-in-long-term-remains-on-jpmorgans-focus-list" rel="noreferrer noopener">Ultragenyx Stays On JPMorgan&#8217;s Focus List As Analyst Highlights Strong Long-Term Positioning</a>
William Blair initiated coverage <a href="https://www.benzinga.com/quote/RARE/analyst-ratings">with an Outperform rating</a>, writing that the company is at an inflection point. Potentially, six additional therapeutics will be approved by the end of 2028, including three approvals in the next 18 months.
Corwin notes that these additional assets synergize with Ultragenyx&#8217;s existing commercial portfolio, aiding in strong commercial launches. She projects the company&#8217;s expanding revenue stream, supplemented by the potential receipt of three priority review vouchers, could enable the company to achieve GAAP profitability in 2027 and beyond.
William Blair noted that regulatory decisions and clinical data could be catalysts for the stock in the near term. Specifically, positive results from the Phase 3 trial of setrusumab in osteogenesis imperfecta (OI) could lead to significant upside.
Corwin projects the products could begin contributing to the top line as early as the fourth quarter of 2025 and could lead to a major revenue inflection in 2026 with the potential approval of pertuzumab in OI.
William Blair views setrusumab as a blockbuster product and estimates peak revenue of $2.4 billion in 2037, $1.4 billion of which will go to Ultragenyx.
Price Action: RARE stock is down 1.65% at $34.50 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45629309/why-is-rare-lung-disease-focused-savara-stock-trading-lower-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?</a></li>
</ul>
Photo: Shutterstock

Initiation

RARE

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) shares are trading higher on Wednesday after the company announced the appointment of a new CEO on Tuesday, and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/sports/25/05/45632213/vail-resorts-stock-climbs-after-company-announces-ceo-transition" rel="noreferrer noopener">reaffirmed 2025 guidance.</a>
Vail Resorts announced that&nbsp;Rob Katz, executive chair and former CEO, has been appointed current CEO. Katz will succeed&nbsp;Kirsten Lynch, who has stepped down as CEO and as a director of the board.
Here are the key analyst takes on the development:
<ul class="wp-block-list">
<li>JP Morgan analyst Matthew R. Boss upgraded the stock from Underweight to Neutral, with a price forecast of $167.</li>
<li>BofA Securities analyst Shaun C. Kelley reiterated the Neutral rating on the stock, raising the price forecast from $160 to $175.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45645056/gold-etf-bleeds-money-at-fastest-pace-in-3-years-is-the-safe-haven-trade-over" rel="noreferrer noopener">Gold ETF Bleeds Money At Fastest Pace In 3 Years — Is The Safe-Haven Trade Over?</a>
<h2 class="wp-block-heading">JP Morgan</h2>
JP Morgan analyst Boss stated in the analyst note that with Vail Resorts nearing the end of industry normalization challenges by FY25 and former CEO Katz returning to lead, the company may be approaching an inflection point in both revenue and earnings.
This outlook is backed by unique growth drivers, Vail Resorts's portfolio of top-tier resorts—including the five most visited in North America—and its advance commitment strategy through various Epic Pass options, which helps reduce seasonal risk.
Boss sees a unique chance for the firm to accelerate its model under returning CEO Katz, who previously led Vail Resorts from 2006 to 2021 and now resumes his leadership role.
With a history of driving double-digit EBITDA growth over 15+ years and a focus on meaningful, quality-driven expansion, Katz may help the company recapture around 250bps of EBITDA margin versus FY19 through stronger operating leverage.
<h2 class="wp-block-heading">BofA Securities</h2>
Bank of America analyst Kelley writes that Katz's return signals urgency, highlighted by a 10% after-hours stock jump and expectations of renewed revenue momentum.
While major shifts to Vail's commitment strategy, efficiency plans, or dividend approach seem unlikely for now, Katz, who previously led transformative initiatives like the Epic Pass and M&amp;A, could drive reinvention, given his role in shaping the industry's current model.
Price Action: MTN shares are trading higher by 12% to $169.66 at last check Wednesday.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655193/applovins-valuation-reflects-high-expectations-for-monetization-expansion-analyst" target="_blank" rel="noreferrer noopener">AppLovin&#8217;s Valuation Reflects High Expectations For Monetization Expansion: Analyst</a></li>
</ul>
Photo by Simone Hogan via Shutterstock

Upgrades

Vail Resorts CEO Shake-Up Spurs Hopes Of Growth Rebound

JPMorgan analyst Sebastiano Petti maintained an Overweight rating on United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) and lowered the<a href="https://www.benzinga.com/quote/usm/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast from $88 to $85</a>.
The analyst says that he foresees additional opportunities to unlock value and anticipates substantial capital returns for shareholders within the next year.
The analyst notes the commencement of T-Mobile&#8216;s exchange offer for up to $2.044 billion of US Cellular debt, which he believes indicates the deal&#8217;s imminent close in the coming weeks, as such offers typically <a target="_blank" href="https://www.benzinga.com//node/43883619" rel="noreferrer noopener">precede closing within 40 days</a>.
Consequently, Petti now expects T-Mobile&#8217;s acquisition of US Cellular&#8217;s wireless operations to finalize on July 1, aligning with expectations for a mid-2025 close.
The analyst now estimates that the company could distribute up to $28-$30 per share in special dividends by mid-2026.
This comprises of an estimated $9-$11 per share from the T-Mobile deal, an additional $10 per share following the sale of spectrum to AT&amp;T, and $9 per share from the Verizon spectrum deal, says the analyst.
The analyst notes that USM continues its focus on cost optimization, but increased industry-wide competition is expected to impact its 2025 financials.
Petti raised the 2025 service revenue estimate to $2.95 billion (up 0.3%) due to higher postpaid ARPU, which is projected to grow 1.2% year-over-year to $52.44, despite anticipated lower volumes in postpaid, handset, and prepaid segments.
Conversely, the analyst lowered 2025 EBITDA estimate by 3% to $970 million, resulting in margins of 26.4% (down from 26.9%).
Although first-quarter capital spending was significantly below the expectations ($53 million versus $133 million prior), the analyst is only marginally trimming 2025 capital expenditure by 2% to $520 million.
Price Action: USM shares are down 0.76% at $62.80 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45465922" target="_blank" rel="noreferrer noopener">Charter Seals&nbsp;$34.5 Billion&nbsp;Cox Merger Deal, Creating Powerhouse To Battle Streaming, Wireless Rivals</a></li>
</ul>
Photo: Shutterstock

US Cellular Deal Could Unlock Major Payouts: JPMorgan Expects T-Mobile Acquisition To Finalize By July

Stock Split

VXRT

Vaxart Board Commits To High End Of 1-for-20 Reverse Stock Split Ratio

Needham analyst Bernie McTernan <a target="_blank" href="https://www.benzinga.com/quote/APP/analyst-ratings" rel="noreferrer noopener">reiterated its Hold rating</a> on AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) on Wednesday.
AppLovin&#8217;s primary tool for future growth is <a target="_blank" href="https://www.benzinga.com/insights/analyst-ratings/25/05/45642953/where-applovin-stands-with-analysts" rel="noreferrer noopener">Axon 2</a>, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
In McTernan&#8217;s third AppLovin Ecommerce Tracker, the total number of websites in his sample using Axon grew by +3% compared to last month to 323, which includes 18 gross adds and 7 churns.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323056/applovins-rapid-ad-growth-ai-gains-drive-hike-in-analyst-price-forecast" rel="noreferrer noopener">AppLovin&#8217;s Rapid Ad Growth, AI Gains Drive Hike In Analyst Price Forecast</a>
The seven churned websites were more than the one churn last month, the analyst noted. However, two of the seven companies shut down their businesses, he said in the analyst note.
McTernan said Apparel, Footwear &amp; Accessories was the largest category gainer in the past month, with 10 gross adds and one churn.
The analyst noted that AppLovin announced in December that the company had 600 e-commerce brands and a $1 billion ad spend run rate.
Given the relatively modest growth and essentially unchanged pixel helper count, he does not believe self-service has launched yet.
McTernan noted one big brand add the Pixel this month, Reebok, which Authentic Brands Group, a private brand management company, owns. Press reports indicate Reebok does ~$5 billion in sales, which is in the bottom quartile for revenue among the 70 big brands he sampled. Authentic Brands Group combined for $32 billion+ of revenue, the analyst said. Some of the brands that added the Pixel include Champion, Juicy Couture, and Vince Camuto, he said.
Other brands ABG owns but not using the Pixel include Nautica, Aeropostale, Lucky, Brooks Brothers, Sperry, Spyder, Ted Baker, Forever 21, Hunter, McTernan noted.
As a reminder, the analyst noted that focusing on some of the larger brands in his dataset is essential as they have the most remarkable ability to scale advertising spending on the platform. He considered ~70 websites in his tracker big brands.
McTernan noted no change to AppLovin&#8217;s reported user count for the Axon pixel at 2k. The analyst noted that the user count crossed from 1k to 2k between February 28 and March 5, which he noted means the user count passed 1,500 that week.
AppLovin projected second-quarter revenue of $1.21 billion and EPS of $1.86.
Weighing in on AppLovin&#8217;s valuation, McTernan stated that the company&#8217;s valuation has become one of the most expensive within their coverage group. This surge is driven by heightened expectations for the company&#8217;s ability to further monetize its advertising platform through new verticals, he noted.
Price Action:&nbsp;APP stock is trading higher by 1.29% to $385.83 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45380609" target="_blank" rel="noreferrer noopener">AppLovin Stock Surges On Strong Q1 Earnings And Tariff Truce Tailwinds</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Reiteration

AppLovin's Valuation Reflects High Expectations For Monetization Expansion: Analyst

BHVN

Biohaven Announces Plans To Initiate Pivotal Trials In Graves' Disease And In IgA Nephropathy In 2H 2025 And 1H 2026

On Friday, BOfA Securities analyst hosted Richard Aboulafia, a partner at AeroDynamic Advisory, to discuss expectations <a href="https://www.benzinga.com/analyst-ratings/analyst-color" target="_blank" rel="noreferrer noopener">for the upcoming 2025 Paris Air Show</a>.
The analyst says that regarding news of potential 50% EU tariffs, Aboulafia warned that the Air Show could foreshadow how future <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom" target="_blank" rel="noreferrer noopener">international negotiations might unfold</a>.
The analyst notes that the EU might draw lessons from recent agreements in China and the Middle East, which mainly included aerospace and defense products.
Nevertheless, the analyst writes that given the EU&#8217;s own substantial aerospace and defense industry, which it aims to protect, U.S. aerospace and defense interests might become a point of contention rather than an incentive in these discussions.
Also Read: <a href="https://www.benzinga.com//node/45594990" target="_blank" rel="noreferrer noopener">DOJ Offers Boeing Deal To Avoid Criminal Charges Over 737 Max Crashes</a>
Regarding Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Aboulafia views recent deals in the Middle East and China as setting a precedent for other nations&#8217; trade negotiations, suggesting orders will be held back as bargaining chips, noted the analyst.
The analyst writes that, for both Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSY#OTC">EADSY</a>) and Boeing, Aboulafia doesn&#8217;t foresee many airlines placing large new orders, primarily due to a lack of new aircraft programs and existing backlogs exceeding 10 years for their most popular models.
Further, the analyst noted that, as previously disclosed, Aboulafia doesn&#8217;t anticipate any major new commercial aircraft program unveilings due to ongoing supply chain issues and global macroeconomic constraints.
In the defense sector, Aboulafia expects numerous companies to compete for subsystem roles on programs like NGAD/the F-47 and CCA.
Additionally, Aboulafia anticipates an outsized presence of unmanned aerial systems at the show, predicting a focus on lower-tech, expendable variants rather than highly sophisticated systems, says the analyst.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45583103" target="_blank" rel="noreferrer noopener">Trump&#8217;s Chosen Air Force One Contractor L3Harris To Pay $62 Million As Settlement For Misleading US Military</a></li>
</ul>
Photo: Shutterstock

European Aeronautic Defence And Space Unsponsored

EADSY

Will Paris Air Show Signal Shift In Aerospace Trade? Analyst Flags EU Tariff Risks, Order Delays

In a corporate cage match, two of the globe&#8217;s most dominant oil titans are fighting it out for a share of one of the world&#8217;s most coveted oil finds: Guyana. But while Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) are in the midst of arbitration, ETF investors may need to hold on tight. This courtroom battle could rock some of the <a href="https://www.benzinga.com/etfs">largest energy ETFs available</a>.
<h1 class="wp-block-heading">The Stakes: Oil, Ego — And An 11 Billion Barrel Bonanza</h1>
Behind the fight is Hess Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) 30% interest in a huge Guyanese oil project, which has roughly 11 billion barrels in projected reserves. Chevron said in 2023 it agreed to buy Hess for $53 billion, a transaction that would put it at the front of the Guyana boom. 
But Exxon, which already <a href="https://www.benzinga.com/markets/equities/24/06/39479711/exxon-mobil-rakes-in-billions-from-guyana-oil-deal-net-margin-tops-chip-giant-report">co-leads the Guyana project</a>, says it has pre-emptive rights to the stake. Arbitration gets underway in London this week, and sometime in late summer, a panel will <a href="https://www.benzinga.com/topic/oil">make a decision</a>.
<h1 class="wp-block-heading">ETF Fallout: Who&#8217;s Exposed To What?</h1>
The heavy hitters such as Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) and Vanguard Energy Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>) are carrying heavy loads of both Exxon and Chevron, between 35% and 40% combined weighting in each fund.
If either Exxon or Chevron prevails, one can anticipate a pop for these ETFs as the Guyana deal would mean long-term growth assets for the prevailing company.
Hess Corp. is smaller but essential in this saga. ETFs such as iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) carry meaningful exposure to Hess, and therefore a front-row seat to either a lucrative M&amp;A payday or a disappointing fizz.
Additionally, merger arbitrage ETFs, such as NYLI Merger Arbitrage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNA#NYSE">MNA</a>) and ProShares Merger ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MRGR#BATS">MRGR</a>), are likely to be betting on the Hess factor already. If the transaction gets delayed or blocked further, one can expect some readjustment.
<h1 class="wp-block-heading">Beyond the Big Oil Bets</h1>
As Chevron cuts jobs and balances new resources in Kazakhstan and the Gulf of Mexico, it also deals with <a href="https://www.benzinga.com/markets/25/02/44000386/trump-shuts-down-chevrons-venezuela-oil-permit-tightening-pressure-on-maduro-regime-crude-oil-prices-rise-on-supply-concerns">uncertainty in Venezuela</a>, where an operating license may be withdrawn. Exxon is increasing <a href="https://corporate.exxonmobil.com/locations/guyana/guyana-project-overview">production </a>in Guyana to 1.3 million barrels/day by 2027, greater than North Dakota&#8217;s Bakken Shale.
<h1 class="wp-block-heading">One Wrong Move = ETF Domino Effect</h1>
With activist investors watching Exxon and Chevron still under pressure to prove long-term growth, the arbitration&#8217;s outcome could drive major portfolio re-weightings, flows into specific funds or a rise in thematic oil and gas ETFs.
In short, this isn't just a battle over barrels, it's about which ETFs end up doing well and which might need a Band-Aid.
<h1 class="wp-block-heading">Final Thought</h1>
This Guyana brawl might be happening in a London arbitration chamber, but its aftershocks will be felt through world markets and ETF tickers. For investors, it&#8217;s time to look beyond the barrel and begin peering at the ticker tape.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45647794/why-kre-is-falling-behind-xlf-and-raising-flashbacks-of-the-svb-collapse-etf-market-senses-bank-trouble">KRE Falls Behind XLF, Sparks SVB Collapse Flashbacks: Are ETFs Sensing Bank Trouble?</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Commodities

Legal

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

iShares Dow Jones US Energy Sector Index Fund

MRGR

Exxon Stock Vs. Chevron: The 11 Billion Barrel Oil War That Could Shake Up Energy ETFs

MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) shares are trading higher Wednesday, continuing a sharp upward move fueled by retail momentum and recent announcements about the company's<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45622723/microcloud-hologram-stock-is-moving-higher-tuesday-whats-going-on"> progress in quantum technologies</a>.
What To Know: MicroCloud Hologram shares have gained over 80% during intraday trading Wednesday, with volume exceeding 43 million shares, well above its 100-day average of 1.1 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The rally appears to be retail-driven as traders highlight the company's recent quantum initiatives. 
Last week, MicroCloud disclosed it had developed a new quantum supervised learning method, indicating it addresses key limitations in current quantum machine learning algorithms. The company also reported advances in quantum-enhanced imaging, specifically using holographic LiDAR based on time-frequency entanglement to achieve a 40dB signal-to-noise ratio. This technology advancement reportedly enables imaging of non-reflective targets in noisy environments.
The recent developments have gained traction on social media platforms as retail traders react to both the technical potential and the stock's low float. Only 4.73 million shares are available for public trading, and 13.52% of the float is currently sold short, which is likely contributing to increased volatility in the name. Institutional ownership remains minimal at just 0.32%, underscoring the retail-driven nature of the move.
Despite the current rally, MicroCloud shares remain down nearly 95% year-to-date. The stock hit a 52-week low of $5.37 last week before reversing course. The ongoing momentum highlights how small-cap, low-float stocks like MicroCloud can see sharp price increases in response to news flow combined with increasing retail interest.
HOLO Price Action: MicroCloud Hologram shares were up 82.8% at $11.04 at the time of publication Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45651401/wall-street-stalls-as-treasury-yields-climb-again-ahead-of-nvidia-earnings-fed-minutes-whats-driving-markets-wednesday">Wall Street Stalls As Treasury Yields Climb Again Ahead Of Nvidia Earnings, Fed Minutes: What&#8217;s Driving Markets Wednesday? </a></li>
</ul>
Image: Shutterstock.

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MicroCloud Hologram Stock Is Surging Again: What's Going On?

Press Releases

Grab to Announce Second Quarter 2024 Results on August 15, 2024

Grab Reports Second Quarter 2024 Results

Grab to Announce Third Quarter 2024 Results on November 12, 2024

UPDATE - Grab to Announce Third Quarter 2024 Results on November 11, 2024

Grab Reports Third Quarter 2024 Results

Superapp Grab Selects AWS as its Preferred Cloud Provider to Drive Technology Innovation and Growth

Levi & Korsinsky, LLP and Pomerantz LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Grab Holdings Limited and Altimeter Growth Corp. Securities

AMZN

Avis Budget Gr

Hertz Global Holdings, Inc - Common Stock

Hertz Global Holdings

Lyft

Marti Technologies, Inc. Class A Ordinary Shares

Marti Technologies

Ryde Group

Swvl Holdings

Uber Technologies

Webus International Limited - Ordinary Shares

Webus International

JP Morgan

Barclays

Benchmark

HSBC

B of A Securities

수요일(19일) 미국 주요 지수는 다우존스 산업평균지수와 S&amp;P 500 지수가 각각 0.2% 가까이 상승한 44,627.59포인트 및 6,144.15포인트를 기록하며 상승 마감했다. 나스닥 지수는 0.07% 상승한 20,056.25포인트로 마감했다.



수요일에 소매 투자자와 트레이더들의 주목을 받은 상위 종목은 다음과 같다. 



팔란티어 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)



수요일 팔란티어 테크놀로지스는 주가가 10.08% 하락하여 112.06달러에 마감했다. 장중 최고가 125.41 달러, 최저가 108.56 달러였으며 52주 범위는 20.33~125.41달러이다. 팔란티어 주가 하락은 트럼프 행정부가 국방부에 <a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch">상당한 예산 삭감에 대비</a>하라는 지시에 따른 것으로, 팔란티어와 같은 국방 관련 주식에 영향을 미칠 수 있다. 국방부의 예산 삭감은 향후 5년간 매년 8%가 될 것으로 예상된다.



카바나 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)



카바나 주가는 0.95% 하락하여 281.82달러로 마감했다. 장중 최고가는 292.84달러, 최저가는 280.20달러였고, 52주 범위는 48.15~292.84달러다. 이번 하락은 카바나가 예상치를 뛰어넘는 35억 5천만 달러의 매출로 <a href="https://in.benzinga.com/news/earnings/25/02/43831159/carvana-stock-hits-the-brakes-following-q4-earnings-revenue-beat-eps-beat-upbeat-guidance-this-is-just-the-beginning">강력한 4 분기 실적</a>을 보고했음에도 불구하고 발생했다. 또한 주당 56센트의 수익을 보고하여 예상치를 상회했다.



에노빅스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)



에노빅스 주가는 0.27% 소폭 상승하며 11.19달러로 마감했다. 장중 최고가 11.42달러, 최저가 10.76달러를 기록했으며, 52주 범위는 5.70달러에서 18.68달러 사이다. 에노빅스는 <a href="https://in.benzinga.com/news/earnings/25/02/43831159/carvana-stock-hits-the-brakes-following-q4-earnings-revenue-beat-eps-beat-upbeat-guidance-this-is-just-the-beginning">4분기 매출</a>이 972만 달러로 예상치를 상회했다고 발표했다. 그러나 향후 분기에 대한 약세 가이던스는 투자자들의 열정을 약화시켰다.



그랩 홀딩스 (NASDAQ:<a href="https://www.benzinga.com/quote/grab">GRAB)</a>



그랩 홀딩스 주가는 0.75% 상승하여 5.34달러로 마감했다. 장중 최고가는 5.37달러, 최저가는 5.10달러이며 52주 범위는 2.98~5.72달러다. 그랩 주가는 싱가포르의 2025년 예산 발표 이후 50%의 법인세 환급이 기업이 비용 상승에 대처하는 데 도움이 될 수 있다는 소식에 <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43794012/grab-shares-rise-following-singapores-2025-budget-announcement">상승세를 보였다</a>.



테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)



테슬라 주가는 1.82% 상승하여 360.56달러에 마감했다. 장중 최고가 367.34달러, 최저가 353.67달러를 기록했으며, 52주 범위는 138.80달러에서 488.54달러 사이다. 이러한 상승세는 인도에서의 성장을 지원하기 위해 인재를 고용하려는 테슬라의 인도 <a href="https://www.benzinga.com/tech/25/02/43805175/elon-musks-tesla-prepares-for-india-expansion-engineer-confirms-hiring-push-we-are-looking-for-motivated-talent-to-help-us">확장 계획</a> 소식 이후 나타났다.



<a href="https://www.benzinga.com/premarket">벤징가 프리마켓 주요 동향 및 뉴스</a>와 함께 오늘의 거래를 준비하세요.



이미지: Shutterstock 



Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.



독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일(18일) 싱가포르의 저명한 기업가 아담 쿠는 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)의 투자 잠재력에 대한 의문을 제기했다. 동남아시아 슈퍼 앱인 그랩의 주가가 8동남아시아 슈퍼 앱의 주가가 화요일에 8.16% 상승한 5.30달러를 기록했고 지난 1년 동안 51.86% 상승했다.
무슨 일 있었나: 아담 쿠는 소셜미디어 플랫폼 엑스(X)를 통해 이렇게 밝혔다. "나는 동남아시아에 거주하며 개인적으로 교통수단을 이용하고 음식을 주문할 때 매일 그랩 앱을 사용한다. 하지만 경제적 해자가 튼튼하지 않다고 생각하기 때문에 이 주식에 투자하지 않을 것이다.&#8221; 그는 그랩의 시장 지위에 대한 원론적인 관점을 제시했다.
가격이 인상되는 경우 사용자들이 ZIG, 고젝(GoJek) 또는 푸드 판다(Food Panda) 같은 경쟁업체로 얼마나 쉽게 전환하는지 언급하며 플랫폼의 제한된 가격 책정력을 강조했다.
아담 쿠는 &#8216;멀티배거&#8217; 투자로서 그랩의 잠재력에 회의적인 이유는 현재 8개국에 진출해 있는 동남아시아를 넘어서는 성장 전망이 제한적이기 때문이다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/search?q=%24GRAB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GRAB</a> stock is up 15% today and I see so many people calling it the next big multi bagger. Really? 
I live in Southeast Asia and I personally use the GRAB app everyday for transport and for ordering food. 
But I will not invest in the stock because I think it does not have a…
&mdash; Adam Khoo (@adamkhootrader) <a href="https://twitter.com/adamkhootrader/status/1891798851109126453?ref_src=twsrc%5Etfw">February 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
왜 중요한가: 14명의 애널리스트가 현재 거래 수준보다 낮은 5.14달러의 <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings" target="_blank" rel="noopener">컨센서스 목표주가</a>를 유지하고 있는 만큼 아담 쿠의 평가는 최근 애널리스트들의 정서와 일치한다.
싱가포르에 본사를 둔 209억 9,000만 달러 규모의 그랩은 2012년 설립 이래 차량 호출부터 금융 서비스까지 다양한 서비스를 제공하는 종합 플랫폼을 구축해 왔다.
그러나 최근 HSBC, 뱅크오브아메리카 증권, 차이나 르네상스에서 제시한 평균 주가는 5.25달러로, 주가의 강한 모멘텀에도 불구하고 상승 여력이 제한적이라는 점을 시사하며 그랩의 성장 제약에 대한 아담 쿠의 논지를 뒷받침하고 있다.
<img loading="lazy" decoding="async" class="alignnone size-medium" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19031054/image-159.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920" width="932" height="342" />
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 작성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난 1년간 주가 52% 상승한 그랩, 취약한 "경제적 해자"와 성장 한계 경고

<h2 class="wp-block-heading">블록에 등장한 신규 기업들</h2>
팜켐(OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCHM#OTC">PCHM</a>), 약물 감지 땀 패치의 대표 기업이 전략적 대안을 모색하고 있다(즉, 인수합병 또는 매각). 이사회는 지금까지 은행가를 고용하는 것보다 독자적으로 상황을 처리할 수 있다고 자신감을 나타냈다. 관심 있는 인수자는 <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">공식 데이터룸</a>에 접근할 수 있다.
이번 주 경매 블록의 다른 아이템들:
<ul>
<li>온타리오 교원연기금(Ontario Teachers&#8217; Pension Plan)이 라자(Lazard)를 고용하여 컴플라이언스 소프트웨어 회사 미트라테크(Mitratech)의 매각 프로세스를 운영하도록 했다. 로이터는 거래 규모가 약 40억 달러에 이를 것으로 추정하고 있다.</li>
<li>페이세이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>)가 2020년에 <a href="https://www.benzinga.com/news/20/12/18678982/paysafe-goes-public-again-in-spac-deal-what-investors-should-know">SPAC을 통해 상장된</a> 것을 기억하자. 현재, 블룸버그에 따르면 <a href="https://www.bloomberg.com/news/articles/2025-02-06/paysafe-is-said-to-weigh-sale-after-getting-takeover-interest?srnd=phx-deals">매각 대상</a>이 되고 있다. 억만장자 빌 폴리(Bill Foley)가 지원하는 이 회사는 인수 관심을 받고 있다.</li>
<li>스위스에 본사를 둔 뱅크 J. 사프라 사라신(Bank J. Safra Sarasin)은 덴마크의 삭소 은행에 대한 인수 제안을 검토 중이다. 이는 <a href="https://www.bloomberg.com/news/articles/2025-02-03/safra-sarasin-is-said-to-explore-deal-for-denmark-s-saxo-bank?srnd=phx-deals">블룸버그</a>에 의해 보도되었다.</li>
</ul>
<h2 class="wp-block-heading">블록에서의 업데이트</h2>
<ul>
<li>베리타스 캐피털(Veritas Capital)은 월스트리트 데이터 제공업체 던 앤 브래드스트리트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNB#NYSE">DNB</a>)를 인수하기 위해 접촉 중이다. <a href="https://www.bloomberg.com/news/articles/2025-02-07/veritas-is-said-in-talks-to-acquire-data-firm-dun-bradstreet?srnd=phx-deals">블룸버그</a>에 따르면, 던 앤 브래드스트리트의 시장 가치는 49억 달러이다.</li>
<li>바슈 + 롬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>)은 바슈 헬스 컴퍼니스(Bausch Health Companies Inc.)와의 &#8220;완전 분리&#8221;를 고려했다. 잠재적 구매자들과의 협상 후, 그 과정은 거래로 이어지지 않았다. 이 회사는 완전한 분리를 목표로 하고 있음을 확인했다. 2024년 전체 연간 수익은 2월 19일에 발표될 예정이다.</li>
<li>KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)는 일본 기술 그룹 후지 소프트를 인수하려고 한다. 이 사모펀드는 경쟁사 베인 캐피털를 제치기 위해 제안을 약 43억 달러로 인상했다.</li>
<li>베인은 후지 소프트 거래가 성사되지 않을 경우를 대비해 다른 거래를 진행 중이다. <a href="https://www.bloomberg.com/news/articles/2025-02-06/bain-is-said-to-near-3-billion-deal-for-mitsubishi-pharma-unit?srnd=phx-deals">블룸버그에 따르면</a>, 이 회사는 미츠비시 케미컬 홀딩스(TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:4188#TYO">4188</a>)의 제약 부문을 인수하기 위해 거의 33억 달러 이상을 지불할 예정이다.</li>
</ul>
<h2 class="wp-block-heading">블록에서 나온 거래들</h2>
<ul>
<li>한편, 베인 캐피털는 밀라크론(Milacron)의 51% 지분을 <a href="https://www.plasticsnews.com/news/hillenbrand-sells-majority-stake-milacron-bain-capital-287m">인수하기로 합의</a>했다. 밀라크론은 플라스틱 가공 장비 및 서비스 제공업체이며, 힐렌브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>)는 이 지분을 2억 8천7백만 달러에 매각했다.</li>
<li>리버우드 캐피털(Riverwood Capital)은 뮌헨에 본사를 둔 소매업체 및 브랜드 가격 책정 플랫폼 퀵리자드(TASE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/qlrd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for QLRD" data-google-interstitial="false">QLRD</a>)를 약 5천2백만 달러에 인수하기로 합의했다.</li>
<li>TPG는 미국의 상업용 규모의 태양광 발전소 소유업체 알투스 파워(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>)를 약 22억 달러에 인수하기로 합의했다.</li>
<li>또 다른 태양광 관련 거래: 턴/리버 캐피털(Turn/River Capital)은 텍사스 오스틴에 본사를 둔 솔라윈즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>)를 44억 달러에 인수하기로 합의했다. 이는 2월 6일 목요일 주가 종가 대비 35% 프리미엄이다.</li>
<li>몬트리올에 본사를 둔 발소프트(Valsoft)는 코아츄 매니지먼트(Coatue Management)와 바이킹 글로벌 인베스터(Viking Global Investors)의 지원을 받아 브라질의 클라우드 기반 공증인 관리 소프트웨어 제공업체 VHL 시스테마스(VHL Sistemas)를 인수했다.</li>
<li>BCI, 캐나다 자산 관리 회사가 룩셈부르크에 본사를 둔 투자사 BBGI 글로벌 인프(LSE:BBGIB)를 약 10억 파운드 (12억 4천만 달러)에 인수하기로 합의했다.</li>
<li>EP 글로벌 코머스, 억만장자 다니엘 크레틴스키(Daniel Kretinsky)가 지원하는 회사가 메트로를 20억 유로 (27억 6천만 달러)로 <a href="https://www.bloomberg.com/news/articles/2025-02-06/czech-billionaire-kretinsky-seeks-to-take-metro-private-again?srnd=phx-deals" target="_blank" rel="noopener">인수</a>했다. 이는 독일 뒤셀도르프에 본사를 두고 있다.</li>
<li>데이터브릭스, 620억 달러로 평가된 회사가 블레이드브릿지(BladeBridge)를 <a href="https://www.infoworld.com/article/3817328/databricks-acquires-bladebridge-to-aid-data-warehouse-migrations.html" target="_blank" rel="noopener">인수</a>하여 기업 데이터 웨어하우스 마이그레이션을 강화했다.</li>
<li>JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)은 독일의 세코노미 AG 인수에 대한 관심을 되살렸다고 한다. 이 중국 전자상거래 거인은 2023년에 <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43496221/jd-coms-stock-dips-as-ceconomy-deal-heats-up-in-germany-is-the-e-commerce-king-eyeing-expansion">독일 소매업체에 대한 관심을 마지막</a>으로 나타냈다.</li>
<li>닛산 자동차(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>)의 CEO 우치다 마코토(Makoto Uchida)는 혼다 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>)의 CEO 미베 토시히로(Toshihiro Mibe)에게 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%8B%9B%EC%82%B0-%EC%9E%90%EB%8F%99%EC%B0%A8-ceo-%ED%98%BC%EB%8B%A4-%EC%9E%90%EB%8F%99%EC%B0%A8%EC%97%90-%ED%95%A9%EB%B3%91-%ED%98%91%EC%83%81-%EC%A2%85%EB%A3%8C%EB%A5%BC-%ED%86%B5%EB%B3%B4/" target="_blank" rel="noopener">잠재적 합병 논의를 종료하겠다는 의사를 통보</a>했다.</li>
<li>브룩필드(Brookfield)는 휴스턴에 본사를 둔 전기 열 및 센싱 솔루션 제공업체 케멜렉스(Chemelex)를 17억 달러에 인수하는 거래를 완료했다. 골드만삭스는 엔벤트 일렉트릭(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>)의 매각 측에서 자문을 맡았다.</li>
<li>코트 스퀘어 캐피털 파트너스와 윈드로즈 헬스 인베스터스(WindRose Health Investors)는 텍사스 프리스코에 본사를 둔 주입 회사 솔레오 헬스(Soleo Health)의 11억 달러 인수 거래를 완료했다.</li>
</ul>
<h2 class="wp-block-heading">파산 블록</h2>
판사 크리스토퍼 로페즈(Christopher Lopez)는 알렉스 존스(Alex Jones)의 미디어 회사 인포워스(Infowars)의 두 번째 경매 시도를 용이하게 하는 거래를 거부했다. NPR에 따르면 이 판결은 조에게 또 다른 임시 구제를 제공하지만, 샌디 훅 가족들이 거의 7년 전 부당성 손해배상으로 판결된 13억 달러를 회수하기 위한 노력을 지연시킨다.
로페즈 판사는 인포워스의 모회사인 프리 스피치 시스템(FSS)이 더 이상 파산 상태가 아니기 때문에 거래를 승인할 수 없다고 설명했다. 즉, 그의 판단에 따라 자산은 판매될 수 없으며, 오직 조의 회사 소유 지분만 경매에 부쳐질 수 있다. 그러나 판사는 또한 <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars">이전 제안</a>을 차단했다. 이 제안은 풍자 웹사이트 디 어니언(The Onion)이 샌디 훅 희생자 가족들과 협력하여 인포워스에 입찰한 것이었다.
앞으로 로페즈는 모든 자산 판매는 간단한 현금 거래여야 한다고 강조했다. 이번 결정으로 손해배상 회수 및 조의 플랫폼 해체 가능성에 대한 경로는 여전히 불확실하다.
TGI 프라이데이는 11장소를 포함하여 19개의 추가 매장을 파산 보호 챕터 11 절차의 일환으로 매각했다. 캘리포니아 프리몬트에 본사를 둔 야다브 엔터프라이즈가 300만 달러의 부채로 16개 매장을 인수하고, 슈가로프 호스피텔리티, 전 TGI 프라이데이의 CEO 레이 블란셰트(Ray Blanchette) 소유의 회사가 3개 매장을 10만 달러에 인수하고 있다.
<h2 class="wp-block-heading">블록에서의 노트</h2>
규모 vs 범위: 이번 주 베인 캐피털은 미디어 부문에서의 트렌드를 지적했다.
미디어 거래가 &#8220;주로 산업 간 거래&#8221;가 되고 있다. 베인의 <a href="https://www.bain.com/insights/media-and-entertainment-m-and-a-report-2025/">분석</a>에 따르면, 딜로직(Dealogic)의 데이터를 사용하여 2024년 1~3분기 동안 모든 미디어 산업 M&amp;A의 절반 이상이 목표 또는 인수자가 자사 산업 외부에 있었던 것으로 나타났다.
여기 몇 가지 주목할 만한 사항들이 있다. 베인의 파트너인 니콜 마군, 매트 키스 및 알렉스 이건이 언급했다:
<ul>
<li>과거에는 월트 디즈니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)의 거래 대부분이 &#8220;규모&#8221; (즉, 2006년 Pixar 인수 및 2019년 21세기 폭스 인수)였으나, 현재는 &#8220;범위 거래&#8221;의 비중이 높아지고 있다. 예를 들어, 지난해 디즈니는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41052867/disneys-streaming-surge-epic-games-deal-among-key-growth-drivers-says-analyst">포트나이트의 제작사</a> 에픽 게임즈에 투자했다.</li>
<li>소니 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>)는 알라모 드래프트하우스(Alamo Drafthouse)라는 극장-저녁 식사 체인을 인수했다.</li>
<li>기업들은 또한 지속 가능한 IP를 위한 거래를 진행하고 있다: 소니 뮤직은 마이클 잭슨의 <a href="https://www.benzinga.com/general/entertainment/24/08/40515995/michael-jacksons-1-5b-catalog-lands-court-approval-for-sale-thriller-for-sony">음악 및 저작권 카탈로그</a>의 절반을 인수했다.</li>
<li>팝하우스 엔터테인먼트(Pophouse Entertainment)는 키스(Kiss)의 카탈로그와 <a href="https://www.benzinga.com/general/entertainment/24/04/38116031/sealed-with-a-kiss-rock-band-sells-legacy-for-300m-who-did-gene-simmons-get-into-bed-with">밴드 멤버의 초상권</a>를 인수했다.</li>
<li>사모펀드들은 품질 있는 IP를 보유한 소규모 제작 스튜디오에 투자하고 있다. 예를 들어, 레드버드(Redbird)는 All3Media를 인수하여 영상 분야에서 지속적인 우위를 확보하고자 했다.</li>
</ul>
위험이 있을까? &#8220;산업 간 미디어 M&amp;A에서 인수자는 이러한 거래가 다른 유형의 실사를 요구한다는 것을 빠르게 배운다&#8221;고 베인의 파트너들이 말한다. &#8220;첫째, 인수자는 목표 산업에 덜 익숙할 가능성이 높다. 또한, 범위 거래에 내재된 수익 시너지는 비용 시너지보다 실현하고 평가하기가 더 어렵다.&#8221;
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%84%B8%EC%9D%B4%EC%A7%80%EC%99%80-%EC%8B%A4%EB%B2%84%EC%8A%A4%EA%B0%80-%EB%A7%A4%EA%B0%81-%EC%A4%91-%EB%AF%B8%EC%8A%A4%ED%84%B0%EB%B9%84%EC%8A%A4/" target="_blank" rel="noopener">여기를 클릭하세요.</a>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 심보틱(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/42213634" target="_blank" rel="noreferrer noopener">2025 회계연도 1분기 매출 전망을 하향 조정</a>하고 애널리스트들이 주식의 <a href="https://www.benzinga.com/quote/sym/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 하향 조정</a>한 후 25.83% 급락했다.
2. 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)의 주식은 애널리스트들이 주식을 하향 조정하거나 <a href="https://www.benzinga.com/quote/grab/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 하향 조정</a>한 후 11.82% 하락했다.
3. 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)의 주식은 회사가 글로벌 확장을 가속화하고 인도와 브라질과 같은 국제 시장에 집중하여 <a href="https://www.benzinga.com//node/42221015" target="_blank" rel="noreferrer noopener">사용자 성장과 광고 기회를 확보</a>하려 한다고 발표한 후 10.97% 하락했다.
4. 방쿠 브라데스쿠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBD#NYSE">BBD</a>) 주식은 JP 모건의 애널리스트인 도밍고스 팔라비나(Domingos Falavina)가 회사를 비중확대에서 중립으로 <a href="https://www.benzinga.com/quote/bbd/analyst-ratings" target="_blank" rel="noreferrer noopener">하향 조정</a>한 후 10.88% 하락했다.
5. H 월드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) 주식은 회사가 <a href="https://www.benzinga.com//node/42197824" target="_blank" rel="noreferrer noopener">예상보다 저조한 재무 결과를 발표</a>한 후 10.44% 급락했다.
6. 버티브 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) 주식은 9.82% 하락했다.
7. 이타우 유니방코 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITUB#NYSE">ITUB</a>) 주식은 8.53% 하락했다.
8. 사베스프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBS#NYSE">SBS</a>) 주식은 지난주에 8.40% 하락했다.
9. 델 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)의 주식은 회사가 3분기 실적을 발표하고 여러 애널리스트들이 <a href="https://www.benzinga.com//node/42221770" target="_blank" rel="noreferrer noopener">주식에 대한 전망을 수정</a>한 후 8.16% 하락했다.
10. 뉴타닉스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>)의 주식은 회사가 1분기 재무 실적이 예상보다 좋게 나타났다고 발표했으나, 회사의 1분기 <a href="https://www.benzinga.com//node/42221971" target="_blank" rel="noreferrer noopener">실적이 ARR 감소로 상쇄</a>되었다고 발표한 후 7.98% 하락했다. 여러 애널리스트들이 주식에 대한 가격 예측을 수정했다.
11. 오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)의 주식은 3분기 재무 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/42218196" target="_blank" rel="noreferrer noopener">주식에 대한 목표 가격을 수정</a>한 후 7.98% 하락했다.
이미지 출처: Shutterstock
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B9%84%EC%95%88-%EB%A1%9C%EC%BC%93%EB%9E%A9-%EB%B0%8F-%EB%AA%A8%EB%8D%94%EB%82%98%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ADSK

DELL

HTHT

ITUB

NTNX

RDDT

레딧, 그랩 및 오토데스크 지난주 최악의 성과를 보인 11개 대형주 중 일부 (11월 25일-29일)

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격의 급등으로 인해 지난 주 25.97% 상승했다.
2. 쇼피파이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>)의 주식은 회사가 예상보다 좋은 3분기 실적을 발표하고, 여러 애널리스트가 <a href="https://www.benzinga.com//node/41950175" target="_blank" rel="noreferrer noopener">목표 주가를 상향 조정</a>한 후 24.53% 상승했다.
3. 어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)의 주식은 웰스 파고(Wells Fargo)가 주식에 대해 비중 확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/afrm/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 $52에서 $55로 상향 조정</a>한 후 20.80% 상승했다.
4. 월트 디즈니 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)의 주식은 <a href="https://www.benzinga.com//node/41971559" target="_blank" rel="noreferrer noopener">4분기 실적</a>을 발표한 후 16.22% 상승했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/dis/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측을 상향 조정</a>했다.
5. 스포티파이 테크놀로지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>)의 주식은 회사가 예상보다 좋은 3분기 실적을 발표하고 <a href="https://www.benzinga.com//node/41950852" target="_blank" rel="noreferrer noopener">애널리스트들이 목표 주가를 상향 조정</a>한 후 14.39% 상승했다.
6. 잭 도시의 블록(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>)의 주식은 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/sq/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측을 상향 조정</a>한 후 13.06% 상승했다.
7. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 회사가 온체인 결제 플랫폼 유토피아 랩스(Utopia Labs)를 인수했다고 발표한 후 12.97% 상승했다. 비트코인 가격의 급등도 한몫했다.
8. 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)의 주식은 회사가 리오 틴토(Rio Tinto)와의 다년간 기업 계약을 추가 4년 연장했다고 발표한 후 12.64% 상승했다. 또한 주식 <a href="https://www.benzinga.com//node/42010539" target="_blank" rel="noreferrer noopener">상장 거래소를 나스닥으로 이전할 계획</a>이다.
9. 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)의 주식은 회사가 3분기 실적을 발표하고 FY25 매출 <a href="https://www.benzinga.com//node/41889889" target="_blank" rel="noreferrer noopener">가이던스를 예상 이상으로 상향 조정</a>한 후 11.82% 상승했다.
10. 넷이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41964319" target="_blank" rel="noreferrer noopener">3분기 재무 실적</a>을 발표한 후 11.37% 상승했다.
사진 출처: Useacoin, Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AFRM

COIN

MSTR

NTES

SHOP

SPOT

쇼피파이, 디즈니 및 코인베이스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 11일-15일)

화요일 아침 (현지 시간 기준) 미국 주식 선물이 하락하고 있는 가운데, 오늘 투자자들의 관심을 끌 만한 주식은 다음과 같다.
1. <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 월가에서는 타이슨 푸드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>)의 분기 주당순이익 69센트, 매출 133억 9천만 달러를 예상하고 있다. 타이슨 주식은 애프터마켓에서 1.2% 상승한 59.50달러를 기록했다.
2. 애널리스트들은 오늘 개장 전 실적을 발표하는 홈디포(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)의 분기 주당순이익 3.64달러, 매출 391억 7천만 달러를 예상한다. 홈디포 주식은 애프터마켓에서 0.2% 하락한 407.55달러에 거래되었다.
3. 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)는 3분기 실적이 예상보다 좋았고, 2024년 전망을 상향 조정했다. 분기 주당순이익 1센트는 컨센서스 예상치 주당순손실 1센트를 상회했다. 그랩 주식은 애프터마켓에서 12.3% 상승한 4.92달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
4. 제임스 리버 그룹 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>)는 3분기 실적이 예상보다 저조했다고 발표했다. 주식은 애프터마켓에서 7.1% 하락한 6.15달러에 거래되었다.
5. 애널리스트들은 옥시덴탈 페트롤리엄(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>)의 분기 주당순이익을 74센트, 매출을 72억 3천만 달러로 예상한다. 주식은 월요일 0.6% 상승해 50.81달러로 마감했다.
더 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%94%EC%9A%94%EC%9D%BC-%EC%A3%BC%EB%AA%A9%EB%B0%9B%EC%9D%80-%EC%A3%BC%EC%8B%9D-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C%EC%8A%A4%ED%8A%B8%EB%9E%98%ED%8B%B0%EC%A7%80-%EB%A7%88%EB%9D%BC%ED%86%A4/" target="_blank" rel="noopener">월요일 주목받은 주식: 마이크로스트레티지, 마라톤 디지털, 코인베이스, 클린스파크 및 테슬라</a>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Pre-Market Outlook

JRVR

화요일 주목해야 할 주식: 홈디포, 타이슨 푸드, 그랩, 제임스 리버 및 옥시덴탈 페트롤리엄

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 실적 <a href="https://www.benzinga.com//node/41537560" target="_blank" rel="noreferrer noopener">호조와 전반적인 시장 강세</a>로 인해 21.97% 상승했다.
2. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 중국 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a>($9,836억 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지한 후 14.02% 상승했다.
3. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41500855" target="_blank" rel="noreferrer noopener">3분기 실적을 발표</a>한 후 12.36% 급등했다.
4. 태피스트리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)의 주식은 자사의 카프리 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) 인수 제안이 <a href="https://www.benzinga.com//node/41550527" target="_blank" rel="noreferrer noopener">법원에 의해 차단되었다는 보도</a> 이후 11.83% 상승했다. 이 회사는 이 결정에 대해 항소할 계획이라고 밝혔다.
5. 앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/APP/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 11.30% 상승했다.
6. 부즈 앨런 해밀턴 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>)의 주식은 2분기 재무 실적이 예상보다 좋게 나타나고 <a href="https://www.benzinga.com//node/41543105" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스가 강하게 나타난</a> 후 10.99% 상승했다.
7. 디지털 리얼티 트러스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)의 주식은 3분기 FFO 실적이 예상보다 좋고 2024 회계연도 FFO 가이던스를 상향 조정한 후 9.45% 상승했다. 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/DLR/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.
8. 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)의 주식은 다이와 캐피털(Daiwa Capital)이 주식을 아웃퍼폼 등급으로 <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings" target="_blank" rel="noreferrer noopener">커버리지 개시하고 $4.60의 목표 주가를 제시</a>한 후 9.12% 상승했다.
9. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 비트코인 가격 상승으로 <a href="https://www.benzinga.com//node/41544385" target="_blank" rel="noreferrer noopener">8.56% 상승</a>했다.
10. 필립 모리스 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)의 주식은 회사가 3분기 실적이 예상보다 좋게 나타나고 여러 애널리스트들이 목표 주가를 <a href="https://www.benzinga.com//node/41499153" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 8.03% 상승했다.
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Grab Holdings

뉴스

에 대한 최신 뉴스 Grab Holdings (NASDAQ:GRAB) 주식

목요일, 2월 20, 2025

수요일, 2월 19, 2025

토요일, 2월 08, 2025

일요일, 12월 01, 2024

일요일, 11월 17, 2024

화요일, 11월 12, 2024

토요일, 10월 26, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌